This study is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy
of cetirizine and famotidine in reducing the duration of symptoms in patients with COVID-19.
Secondary aims are to determine if cetirizine and famotidine decrease severity and duration
of symptoms, incidence of hospitalizations, ICU admissions, and death.